Hypertension and chronic kidney disease: Controversies in pathogenesis and treatment

Minerva Urologica e Nefrologica

Volumn 65, Issue 1, 2013, Pages 37-50

  Pirkle, J L ^a   Freedman, B I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

APOL1 protein, human; Blood pressure determination; Hypertension; Kidney failure, chronic; Uric acid

Indexed keywords

ALLOPURINOL; APOLIPOPROTEIN L1; APOPROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PLACEBO; UNCLASSIFIED DRUG; URIC ACID;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHROMOSOME 22Q; CHRONIC KIDNEY DISEASE; COGNITION; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GENOTYPE ENVIRONMENT INTERACTION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; HIV ASSOCIATED NEPHROPATHY; HUMAN; HYPERURICEMIA; IN VITRO STUDY; KIDNEY FAILURE; MICROALBUMINURIA; MOLECULAR GENETICS; NONHUMAN; OBESITY; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK REDUCTION; SMOKING; UPREGULATION; URIC ACID BLOOD LEVEL;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLOPURINOL; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS; CAUSALITY; CHRONIC DISEASE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GOALS; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; HYPERURICEMIA; INTERVENTION STUDIES; KIDNEY DISEASES; LIPOPROTEINS, HDL; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS;

EID: 84878752038     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995;25:207-21.
2. Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000;15:1801-7.
3. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047-51.
4. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994;23:655-60. (Pubitemid 24138418)
5. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, et al. The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans. J Am Soc Nephrol 2010;21:1422-6.
6. Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol 1995;141:10-5.
7. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13(5 Suppl):I80-I93.
8. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992;268(21):3085-91.
9. Appel LJ, Wright JT, Jr., Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-29.
10. Wright JT, Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-31. (Pubitemid 35340538)
11. Appel LJ, Wright JT, Jr., Greene T, Kusek JW, Lewis JB, Wang X, et al. Long-term Effects of Renin-Angiotensin System-Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. Archives of Internal Medicine 2008;168:832-9. (Pubitemid 351620085)
12. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002;62:172-80. (Pubitemid 34754060)
13. Ferguson R, Grim CE, Opgenorth TJ. A familial risk of chronic renal failure among blacks on dialysis? J Clin Epidemiol 1988;41:1189-96. (Pubitemid 19036521)
14. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM, Jr. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 1993;21:387-93. (Pubitemid 23132903)
15. Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 2005;25:529-35. (Pubitemid 41816046)
16. Murea M, Freedman BI. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010;19:235-41.
17. Freedman BI, Iskander SS, Buckalew VM, Jr., Burkart JM, Appel RG. Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol 1994;14:90-4. (Pubitemid 24182576)
18. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175-84.
19. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185-92.
20. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009;75:736-45.
21. Freedman BI, Kopp JB, Winkler CA, Nelson GW, Rao DC, Eckfeldt JH, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol 2009;29:626-32.
22. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997;51:244-52. (Pubitemid 27064543)
23. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841-5.
24. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010;128:345-50.
25. Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int 2009;76:297-306.
26. O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, Kottgen A, Coresh J et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011;20:2450-6.
27. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Hellwege JN, Comeau ME et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2012;27:1505-11.
28. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P et al. APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. Journal of the American Society of Nephrology 2011;22:2129-37.
29. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011;22:2119-28.
30. Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J et al. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant 2011;26:3805-10.
31. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2012 [Epub ahead of print].
32. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, Jonassaint JC et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011;155:386-94.
33. Fine DM, Wasser WG, Estrella MM, Atta MG, Kuperman M, Shemer R et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol 2012;23:343-50.
34. Atta MG, Estrella MM, Kuperman M, Foy MC, Fine DM, Racusen LC et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012;82:338-43.
35. Reeves-Daniel AM, Depalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL et al. The APOL1 Gene and Allograft Survival after Kidney Transplantation. Am J Transplant 2011;11:1025-30.
36. Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, Dyer C et al. The APOL1 genotype of african american kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012;12:1924-8.
37. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011;22:2098-105.
38. Freedman BI, Langefeld CD, Turner J, Nunez M, High KP, Spainhour M et al. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 201 [Epub ahead of print].
39. Tzur S, Rosset S, Skorecki K, Wasser WG. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 2012;27:1498-505.
40. Kanji Z, Powe CE, Wenger JB, Huang C, Ankers E, Sullivan DA et al. Genetic Variation in APOL1 Associates with Younger Age at Hemodialysis Initiation. J Am Soc Nephrol 2011;22-2091-7.
41. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol 2010;5:1107-13.
42. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertens 2002;40:355-60. (Pubitemid 35006723)
43. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005;70:343-54. (Pubitemid 40905106)
44. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001;19:1209-15. (Pubitemid 32595276)
45. Nagahama K, Iseki K, Inoue T, Tourna T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004;27:227-33. (Pubitemid 38594393)
46. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33. (Pubitemid 40066409)
47. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303. (Pubitemid 46143005)
48. Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006;48:1037-42. (Pubitemid 44772705)
49. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006;48:1031-6. (Pubitemid 44772704)
50. Rathmann W, Haastert B, Icks A, Giani G, Roseman JM. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol 2007;22:439-45. (Pubitemid 47224907)
51. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003;42:247-52. (Pubitemid 37093468)
52. Loeffler LF, Navas-Acien A, Brady TM, Miller ER, III, Fadrowski JJ. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006. Hypertension 2012;59:811-7.
53. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001;24:691-7. (Pubitemid 33133783)
54. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008;19:1204-11.
55. Obermayr RP, TemmL C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13.
56. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010;56:264-72.
57. Zhang L, Wang F, Wang X, Liu L, Wang H. The association between plasma uric acid and renal function decline in a Chinese population-based cohort. Nephrol Dial Transplant 2012;27:1836-9.
58. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6. (Pubitemid 34252813)
59. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-F997. (Pubitemid 34654464)
60. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002;13:806-16. (Pubitemid 34183950)
61. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604-8. (Pubitemid 21906552)
62. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-93. (Pubitemid 36706079)
63. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-42. (Pubitemid 40577708)
64. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005;16:3553-62. (Pubitemid 46211276)
65. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, Finch J et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004;66:281-7. (Pubitemid 38870104)
66. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
67. Feig DI. Uric acid and hypertension. Semin Nephrol 2011;31:441-6.
68. Leite ML. Uric acid and fibrinogen: age-modulated relationships with blood pressure components. J Hum Hypertens 2011;25:476-83.
69. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9. (Pubitemid 41828266)
70. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011;6:1887-94.
71. GraesslerJ, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006;54:292-300. (Pubitemid 43124109)
72. Lanaspa MA, Tapia E, Soto V, Sautin Y, Sanchez-Lozada LG. Uric acid and fructose: potential biological mechanisms. Semin Nephrol 2011;31:426-32.
73. Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD et al. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int 2010;77:609-16.
74. Gao X, Qi L, Qiao N, Choi HK, Curhan G, Tucker KL et al. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension 2007;50:306-12. (Pubitemid 47205778)
75. Brymora A, Flisinski M, Johnson RJ, Goszka G, Stefanska A, Manitius J. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 2012;27:608-12.
76. Johnson RJ, Sanchez-Lozada LG, Nakagawa T. The effect of fructose on renal biology and disease. J Am Soc Nephrol 2010;21:2036-9.
77. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8. (Pubitemid 351626187)
78. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3. (Pubitemid 351731743)
79. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108):2154-69.
80. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-8. (Pubitemid 26012498)
81. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998;317:720-6.
82. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52. (Pubitemid 28108434)
83. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64. (Pubitemid 30185779)
84. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New Engl J Med 2001;345:851-60.
85. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9. (Pubitemid 41716450)
86. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DCJr, Grimm RH, Jr. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
87. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84. (Pubitemid 24094966)
88. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011;154:541-8.
89. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
90. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ et al. The effect of a lower target blood pressure on the progression of kidney disease: longterm follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51. (Pubitemid 40293407)
91. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46. (Pubitemid 41071427)
92. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
93. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M et al. Guidelines for the management of chronic kidney disease. CMAJ 2008;179:1154-62.
94. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 Suppl 1):S1-290.
95. Pastor-Barriuso R, Banegas JR, Damian J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003;139:731-9.
96. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8.
97. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93. (Pubitemid 46768128)
98. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755- 62. (Pubitemid 28269185)
99. Flack JM, Neaton J, Grimm R, Jr., Shih J, Cutler J, Ensrud K et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995;92:2437-45.
100. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24):3255-64.